

**Remarks:**

The specification has been amended to add a priority claim to the corresponding international application. Accordingly, no new matter has been added by this amendment.


Claims 1-24 and 32-39 are presented for examination. The original claim set in the PCT application contained a typographical error wherein two (2) claims were both numbered as "claim 24". In order to preserve the original claim sequence, the "first claim 24" has been retained whereas the "second claim 24" has been cancelled and presented at the end of the claim set as new claim 32. Also, the remaining original claims 25-31 have been cancelled and presented as new claims 33-39. Claims 3, 4, 5, 6, 9, 13, 14, 15, 16, 17, 19, 20, 21, 22, 23, and 24 have been amended to remove multiple dependencies. Claims 5, 6, 7, 8, 9, 10, 11, 12, and 17 have been amended to insert the phrase "or a pharmaceutically acceptable salt, ester, *N*-oxide, or prodrug thereof" and correct minor punctuation. Support for the amendments presented herein can be found at least in claim 1 as filed. No new matter has been added by these amendments.

If there are any questions regarding these amendments and remarks, the Examiner is encouraged to contact the undersigned at the telephone number provided below.

Although no additional charges are believed to be due, the Commissioner is authorized to charge any additional fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311, Ref. No. 26505-514 NATL.

Respectfully submitted,

Date: August 25, 2006

  
Ivor R. Elrifi, Reg. No. 39,329  
Heidi A. Erlacher, Reg. No. 45,409  
Attorneys for Applicant  
MINTZ, LEVIN, COHN, FERRIS  
GLOVSKY AND POPEO, P.C.  
One Financial Center  
Boston, MA 02111  
Tel: (617) 542-6000  
Customer No. 30623